Matrix Metalloproteinase (MMP) in Heart Failure

The purpose of this study is to evaluate the production of MMP in failing hearts.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Stable Heart Failure Cardiovascular Diseases Heart Diseases Heart Failure

Sex eligibility

All sexes

Study type

Observational

About this study

Myocardial fibrosis is observed in failing hearts and parallel to the progression of chronic heart failure (CHF) and myocardial remodeling. Matrix metalloproteinases (MMPs) are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with CHF. However, MMPs it is still unclear whether MMPs are produced in failing hearts. Thus, the purpose of this study is to evaluate the production of MMP in failing hearts.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

chronic stable heart failure

Treatment and study plan

Primary outcomes

MMPs level of coronary sinus

Sponsors and collaborators

Lead sponsor

Tottori University Hospital

Other

Registry information

Official study title

MMP is Produced in Failing Hearts

Important dates

Study start: 2003
Study completion: 2006
First posted: Apr 22, 2008
Registry last updated: Jul 21, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed